cabozantinib,everolimus,lenvatinib,sunitinib,pembrolizumab,axitinib,atezolizumab
merck,pfizer,eisai,roche
['contact03', 'keynote426', 'key,note,42', 'clear study', 'key,note,426']
 discusses #keynote426 &amp; #clear study abstracts 1] data reinforces front line practices of io/tki but what about favorable risk? 2]contact03 showed immediate rechallenge did not improve os but does not answer the question of long term rechallenge with io #asco23 
Medical Oncologist, Investigator, Chief, #BladderCancer Section, #GenitourinaryTumors, NCI, NIH #RareTumors #PatientAdvocate, Latina. Views are my own